MUE stands for meningoencephalitis of unknown etiology, a condition where a dog’s brain and its surrounding membranes become inflamed without an identifiable infectious cause. It’s one of the most common neurological diseases in dogs, and “unknown etiology” simply means veterinarians can confirm the inflammation but can’t pinpoint exactly what triggered it. The condition is widely believed to be immune-mediated, meaning the dog’s own immune system attacks its brain tissue.
What MUE Actually Covers
MUE is an umbrella term. Underneath it sit several more specific diagnoses that can only be confirmed through tissue analysis after death. The three main subtypes are granulomatous meningoencephalomyelitis (GME), necrotizing meningoencephalitis (NME), and necrotizing leukoencephalitis (NLE). Each affects slightly different parts of the brain and tends to show up in different breeds, but because distinguishing them in a living dog isn’t reliably possible, veterinarians group them under MUE (sometimes also called MUO, for “unknown origin”).
GME is the most common subtype and primarily affects small female dogs. NME is most associated with Pugs. NLE tends to appear in Yorkshire Terriers and French Bulldogs, where it targets the white matter of the brain. In practice, the distinction between subtypes rarely changes the treatment plan, which is why the umbrella diagnosis works well for guiding care.
Breeds at Highest Risk
MUE overwhelmingly affects small and toy breeds. A large multicenter study of referral hospitals in England found that Welsh Springer Spaniels, Maltese, Papillons, Boston Terriers, and French Bulldogs had the highest odds of developing MUE compared to mixed-breed dogs. Maltese dogs were roughly 20 times more likely to be diagnosed than crossbreeds, and Welsh Springer Spaniels were nearly 24 times more likely.
Genetics play a clear role. In Maltese dogs, researchers have identified genes involved in immune regulation and tumor suppression that appear to influence susceptibility. Pugs carrying specific immune system gene variants on chromosome 12 have a roughly 5.5 times greater risk of developing NME compared to Pugs without those variants. Chihuahuas also carry breed-specific genetic markers linked to higher MUE risk. While any dog can develop MUE, the strong breed clustering points to inherited vulnerability, likely triggered by some environmental or internal stimulus that hasn’t been identified yet.
Signs and Symptoms to Recognize
MUE can come on suddenly or build gradually. In a study of juvenile dogs with the condition, about two-thirds presented with acute onset, meaning symptoms appeared and worsened over days rather than weeks. The most common reasons owners brought their dogs in were changes in alertness or awareness, unsteadiness when walking, seizures, and circling behavior.
On neurological examination, the most frequent findings were:
- Altered mental state (71% of dogs), ranging from dullness and disorientation to a blank, unresponsive look
- Balance and coordination problems (53%), including a wobbly, drunken gait or a vestibular lean to one side
- Vision deficits (68%), often noticeable when a dog fails to blink at a hand motion near the eye
- Circling or head turning (44%), where the dog walks in tight circles or consistently looks to one side
- Seizures (29%), which can be the very first symptom an owner notices
- Neck pain (18%), shown by reluctance to lift the head or yelping when touched
Not every dog shows all of these signs. Some dogs present with just seizures and no other obvious deficits. Others lose coordination so quickly that owners initially suspect a stroke. The combination of a young, small-breed dog with rapidly progressing neurological symptoms is one of the clearest clinical red flags for MUE.
How MUE Is Diagnosed
Diagnosing MUE is partly a process of ruling out everything else. Because the inflammation looks similar to infections, tumors, and other brain diseases, the veterinary team needs to exclude those possibilities before settling on MUE. The two primary tools are an MRI of the brain and analysis of cerebrospinal fluid (CSF), the liquid that surrounds the brain and spinal cord.
On MRI, dogs with MUE often show areas of abnormal signal in the brain, but the findings vary widely. Some dogs have dramatic, obvious lesions. Others have subtle changes, and a small number have completely normal-looking MRIs despite having the disease. CSF analysis typically reveals elevated white blood cell counts and protein levels, signs of active inflammation, but again, results can range from markedly abnormal to normal. When both the MRI and CSF come back unremarkable, veterinarians rely on the combination of symptoms, how quickly they progressed, and the dog’s breed and age to make a clinical diagnosis.
The diagnostic workup is not cheap. An MRI with the associated anesthesia and CSF collection typically costs around $5,000 at specialty neurology practices, though prices vary by location. A definitive, tissue-confirmed diagnosis is only possible after death through biopsy, which is why living dogs receive a “presumptive” MUE diagnosis.
Treatment and What to Expect
Treatment centers on suppressing the immune system to stop it from attacking the brain. Nearly every dog with MUE starts on high-dose corticosteroids, typically prednisolone or an equivalent, to bring down inflammation quickly. Once the initial crisis stabilizes, the steroid dose is gradually tapered over months.
Most dogs also receive a second immunosuppressive medication alongside steroids. The specific drug varies based on the neurologist’s preference, the dog’s response, and cost considerations. Common options include cytarabine (given as injections at progressively longer intervals), cyclosporine (a daily oral medication), mycophenolate, or azathioprine. The goal of adding a second drug is to allow a lower steroid dose over time, reducing side effects while maintaining disease control.
Treatment is long-term, often lasting months to years. Some dogs eventually come off all medications. Others need low-dose therapy for life. Your neurologist will adjust the plan based on how your dog responds, typically reassessing every few weeks early on.
Side Effects of Long-Term Medication
Because steroids are the backbone of MUE treatment, the side effects of corticosteroids become part of daily life. The most common ones are increased thirst (reported in about 39% of dogs on steroids), increased urination (28%), vomiting (16%), and diarrhea (15%). Your dog may drink and urinate noticeably more than usual, sometimes leading to accidents in the house. This is a direct drug effect, not a sign that something else is wrong.
Increased appetite and weight gain are also common. Some dogs develop a pot-bellied appearance. A small percentage of dogs show behavioral changes, including restlessness or, rarely, aggression toward people. Dogs older than eight are more than four times as likely to develop excessive thirst and urination on steroids compared to younger dogs. As the dose tapers down, many of these side effects ease.
The second immunosuppressive drugs carry their own risks, most commonly affecting the liver, kidneys, or bone marrow. Your vet will run periodic blood work to catch problems early.
Survival and Long-Term Outlook
The prognosis for MUE is better than many owners expect when they first hear the diagnosis, but it varies enormously from dog to dog. About 82% of dogs survive to leave the hospital after starting treatment, and roughly 64% are still alive at six months. The difficult reality is that 25% to 33% of dogs die within the first week of diagnosis, even with appropriate treatment, typically because the inflammation is too severe or widespread to control quickly enough.
For dogs that respond well to initial treatment, the long-term picture is more encouraging. One study of 73 treated dogs found a median survival exceeding 107 months (nearly nine years) in both dogs with visible MRI lesions and those without. Dogs whose MRIs appeared normal at diagnosis had a statistically better outcome, but both groups showed strong long-term survival. This suggests that dogs who get past the early critical period often do well for years.
Relapse and Ongoing Monitoring
Even dogs that respond beautifully to treatment can relapse, especially during medication tapers. A relapse typically looks like a return of the original symptoms: new seizures, worsening coordination, behavioral changes, or a head tilt that had previously resolved. Some relapses are subtle, showing up as mild lethargy or slight unsteadiness before progressing.
Regular veterinary follow-up is essential throughout treatment. Early on, visits may happen every few weeks to monitor neurological status and blood work. As the dog stabilizes, intervals stretch out. If you notice any return of neurological symptoms between visits, that warrants an immediate call to your vet, since catching a relapse early and adjusting medication quickly tends to produce better outcomes than waiting for the next scheduled appointment.